1 not yet recruiting, 1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Retinitis Pigmentosa 2: new trials by email Literature Review of Retinitis Pigmentosa 2 trials Research Report on Retinitis Pigmentosa 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant RP2 + Nivolumab in Patients With Melanoma RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma | Phase 2 | Not yet recruiting | Yana Najjar | 34 | 2026-12-31 | 2026-10-07 |
| InsightRP2 Registry RP2-associated Retinitis Pigmentosa, X-Linked Retinitis Pigmentosa (XLRP) | Recruiting | University of Göttingen | 200 | 2025-05-01 | 2025-05-21 |
Melanoma (1) · Retinitis Pigmentosa (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Eye Diseases (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Retinal Dystrophies (1)
Nivolumab (1)
University of Göttingen (1) · Yana Najjar (1)
Germany (1) · United States (1)